Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, vol.395, pp.497-506, 2020. ,
Clinical Characteristics of Coronavirus Disease 2019 in China, New Engl. J. Med, 2020. ,
A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, vol.579, pp.270-273, 2020. ,
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. Published, 2020. ,
Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv, 2020. ,
High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation, Obesity, 2020. ,
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N. Engl. J. Med, 2020. ,
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries, Diabetes, Metab. Syndrome Clin. Res. Rev, vol.14, pp.241-246, 2020. ,
A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv, 2020. ,
Compassionate Use of Remdesivir for Patients with Severe Covid-19, New Engl. J. Med, 2020. ,
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, vol.105949, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02525126
, , 2020.
, Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients, Natl. Sci. Rev, vol.13, 2020.
Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med, p.30076, 2020. ,
The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. medrxiv, 2020. ,
Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin. Infect. Dis, vol.12, 2020. ,
Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medrxiv, 2020. ,
Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus, 2020. ,
The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. medRxiv, 2020. ,
Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection, 2020. ,
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease, JAMA Intern. Med, vol.13, 2019. ,
Utility of Ferritin, Procalcitonin, and C-reactive Protein in Severe Patients with 2019 Novel Coronavirus Disease, 2020. ,
Prognostic value of C-reactive protein in patients with COVID-19. medRxiv, 2020. ,
The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv, vol.10, 2020. ,
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, vol.395, pp.1054-1062, 2020. ,
Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv, vol.12, 2020. ,
Adjuvant corticosteroid therapy for critically ill patients with COVID-19. medRxiv, 2020. ,
SARS: systematic review of treatment effects, PLoS Med, vol.3, p.343, 2006. ,
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome, Am. J. Respir. Crit. Care Med, vol.197, pp.757-767, 2018. ,
, Clinical management of severe acute respiratory infection when COVID-19 is suspected. Department of Communications, WHO team, 2020.
Brigham and Women's Hospital COVID-19 Clinical Guidelines. Brigham and Women's Hospital, vol.15, 2020. ,
, Nonsteroidal anti-inflammatory drugs (NSAIDs) and serious infectious complications -Information Point, vol.18, 2019.
Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) -possible lessons from a systematic review of SARS-CoV therapy, Int. J. Infect. Dis, vol.17, pp.792-798, 2013. ,
The cytokine storm of severe influenza and development of immunomodulatory therapy, Cell. Mol. Immunol, vol.13, pp.3-10, 2016. ,
Cytokine release syndrome, J Immunother Cancer, vol.6, p.56, 2018. ,
Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report, Ann. Oncol, 2020. ,
Effective treatment of severe COVID-19 patients with Tocilizumab, 2020. ,
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation, Blood, vol.112, pp.3073-3081, 2008. ,
TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521), Biol. Blood Marrow Transplant, vol.21, pp.67-73, 2015. ,
Altasciences completes phase I study on gimsilumab for ARDS in COVID-19. Altasciences, 2020. ,
Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19, 2020. ,
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet, vol.395, pp.30-31, 2020. ,
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib, J. Microbiol. Immunol. Infect, 2020. ,
Intravenous immunoglobulin therapy in rheumatic diseases, Nat. Rev. Rheumatol, vol.7, pp.349-359, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02455562
Update on the use of immunoglobulin in human disease: a review of evidence, J. Allergy Clin. Immunol, vol.139, pp.1-46, 2017. ,
High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease, Open Forum Infect. Dis, 2019. ,
Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study. medRxiv, 2020. ,
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19, J. Infect, 2020. ,
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?, Nat. Rev. Immunol, vol.13, pp.176-189, 2013. ,
IVIG-mediated effector functions in autoimmune and inflammatory diseases, Int. Immunol, vol.29, pp.491-498, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02455456
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?, Trends Pharmacol. Sci, vol.25, pp.306-310, 2004. ,
Tackling difficult Staphylococcus aureus infections: antibodies show the way, Cell Host Microbe, vol.20, pp.555-557, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02455465
Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv, 2020. ,
SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv, 2020. ,
Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv, 2020. ,
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis, J. Infect. Dis, vol.211, pp.80-90, 2014. ,
Short communication Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antivir. Ther, vol.23, pp.617-622, 2018. ,
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?, Ann. Intern. Med, vol.145, pp.599-609, 2006. ,
Hyperimmune IV Immunoglobulin Treatment: A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe, Influenza A(H1N1) Infection. Chest, vol.144, pp.464-473, 2009. ,
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses, Trends Immunol, 2020. ,
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.2536-2541, 2004. ,
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med, vol.3, p.237, 2006. ,
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. medRxiv, 2020. ,
A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science eabb7269, 2020. ,
A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv, vol.12, 2020. ,
Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis, 2020. ,
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19), Clin. Infect. Dis, 2020. ,
China puts 245 COVID-19 patients on convalescent plasma therapy, 2020. ,
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma, JAMA, 2020. ,
Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. USA Published online, 2020. ,
, Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19, 2020.
, Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19, 2020.
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial, 2020. ,
Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer, Immunity, vol.50, pp.302-316, 2019. ,
The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them, Cell. Microbiol, vol.19, p.12746, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01510317
In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression, J. Exp. Med, vol.206, pp.751-760, 2009. ,
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism, Nat. Med, vol.24, pp.1005-1014, 2018. ,
Revisiting IL-2: Biology and therapeutic prospects, Sci. Immunol, vol.3, p.1482, 2018. ,
Treating human autoimmunity: current practice and future prospects, Sci. Transl. Med, vol.4, pp.125-121, 2012. ,
FDA Accepts IND for NK Cell Therapy CYNK-001 to Treat Patients with COVID-19. CancerNetwork home of the journal ONCOLOGY, 2020. ,
Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, 2020. ,
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv, 2020. ,
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.30, pp.269-271, 2020. ,
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, vol.6, 2020. ,
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv, 2020. ,
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med. Mal. Infect, 2020. ,